Literature DB >> 30546961

TGF-β enhances the cytotoxic activity of Vδ2 T cells.

Christian Peters1, Annika Meyer1, Léonce Kouakanou1, Julia Feder1, Tim Schricker1, Marcus Lettau1, Ottmar Janssen1, Daniela Wesch1, Dieter Kabelitz1.   

Abstract

TGF-β is a pleiotropic cytokine with multiple roles in immunity. Apart from its suppressive activity, TGF-β is a driving cytokine in the differentiation of induced regulatory T cells (iTreg) but also in the polarization of interleukin-9 (IL-9) producing T helper 9 (Th9) T cells. Human Vδ2 expressing γδ T cells exert potent cytotoxicity towards a variety of solid tumor and leukemia/lymphoma target cells and thus are in the focus of current strategies to develop cell-based immunotherapies. Here we report that TGF-β unexpectedly augments the cytotoxic effector activity of short-term expanded Vδ2 T cells when purified γδ T cells are activated with specific pyrophosphate antigens and IL-2 or IL-15 in the presence of TGF-β. TGF-β up-regulates the expression of CD54, CD103, interferon-γ, IL-9 and granzyme B in γδ T cells while CD56 and CD11a/CD18 are down-regulated. Moreover, we show that CD103 (αE/β7 integrin) is recruited to the immunological synapse in γδ T cells. Increased cytotoxic activity of TGF-β-exposed γδ T cells is reduced by anti-CD103 and further diminished upon additional anti-CD11a antibody treatment, pointing to a role of cellular adhesion in the enhanced cytolytic activity. Furthermore, magnetically sorted CD103-positive Vδ2 T cells exhibit superior cytolytic activity. In view of the importance of CD103 for tissue homing of lymphocytes, our results suggest that adoptive transfer of CD103-expressing Vδ2 T cells might favor their homing to solid tumors.

Entities:  

Keywords:  CD103; IFN-gamma; TGF-beta; Vdelta2; gamma/delta T cells

Year:  2018        PMID: 30546961      PMCID: PMC6287804          DOI: 10.1080/2162402X.2018.1522471

Source DB:  PubMed          Journal:  Oncoimmunology        ISSN: 2162-4011            Impact factor:   8.110


  44 in total

1.  CD8+CD103+ tumor-infiltrating lymphocytes are tumor-specific tissue-resident memory T cells and a prognostic factor for survival in lung cancer patients.

Authors:  Fayçal Djenidi; Julien Adam; Aïcha Goubar; Aurélie Durgeau; Guillaume Meurice; Vincent de Montpréville; Pierre Validire; Benjamin Besse; Fathia Mami-Chouaib
Journal:  J Immunol       Date:  2015-02-27       Impact factor: 5.422

2.  TGFβ Signaling Intersects with CD103 Integrin Signaling to Promote T-Lymphocyte Accumulation and Antitumor Activity in the Lung Tumor Microenvironment.

Authors:  Marie Boutet; Ludiane Gauthier; Marine Leclerc; Gwendoline Gros; Vincent de Montpreville; Nathalie Théret; Emmanuel Donnadieu; Fathia Mami-Chouaib
Journal:  Cancer Res       Date:  2016-02-26       Impact factor: 12.701

3.  Integrin alpha E(CD103)beta 7 influences cellular shape and motility in a ligand-dependent fashion.

Authors:  Stephanie Schlickum; Helga Sennefelder; Mike Friedrich; Gregory Harms; Martin J Lohse; Peter Kilshaw; Michael P Schön
Journal:  Blood       Date:  2008-05-20       Impact factor: 22.113

4.  Quantitative analysis of Th1, Th2 and TGF-beta1 cytokine expression in tumor, TIL and PBL of non-small cell lung cancer patients.

Authors:  C Asselin-Paturel; H Echchakir; G Carayol; F Gay; P Opolon; D Grunenwald; S Chouaib; F Mami-Chouaib
Journal:  Int J Cancer       Date:  1998-07-03       Impact factor: 7.396

5.  CD103 or LFA-1 engagement at the immune synapse between cytotoxic T cells and tumor cells promotes maturation and regulates T-cell effector functions.

Authors:  Katarzyna Franciszkiewicz; Audrey Le Floc'h; Marie Boutet; Isabelle Vergnon; Alain Schmitt; Fathia Mami-Chouaib
Journal:  Cancer Res       Date:  2012-11-27       Impact factor: 12.701

6.  Robust tumor immunity to melanoma mediated by interleukin-9-producing T cells.

Authors:  Rahul Purwar; Christoph Schlapbach; Sheng Xiao; Hong Soon Kang; Wassim Elyaman; Xiaodong Jiang; Anton M Jetten; Samia J Khoury; Robert C Fuhlbrigge; Vijay K Kuchroo; Rachael A Clark; Thomas S Kupper
Journal:  Nat Med       Date:  2012-07-08       Impact factor: 53.440

Review 7.  Alpha E: no more rejection?

Authors:  Peter J Kilshaw; Jonathan M G Higgins
Journal:  J Exp Med       Date:  2002-10-07       Impact factor: 14.307

8.  Alpha E beta 7 integrin interaction with E-cadherin promotes antitumor CTL activity by triggering lytic granule polarization and exocytosis.

Authors:  Audrey Le Floc'h; Abdelali Jalil; Isabelle Vergnon; Béatrice Le Maux Chansac; Vladimir Lazar; Georges Bismuth; Salem Chouaib; Fathia Mami-Chouaib
Journal:  J Exp Med       Date:  2007-02-26       Impact factor: 14.307

9.  Anticancer Tc9 cells: Long-lived tumor-killing T cells for adoptive therapy.

Authors:  Yong Lu; Qiang Wang; Qing Yi
Journal:  Oncoimmunology       Date:  2014-04-29       Impact factor: 8.110

10.  C-C chemokine receptor type-4 transduction of T cells enhances interaction with dendritic cells, tumor infiltration and therapeutic efficacy of adoptive T cell transfer.

Authors:  Moritz Rapp; Simon Grassmann; Michael Chaloupka; Patrick Layritz; Stephan Kruger; Steffen Ormanns; Felicitas Rataj; Klaus-Peter Janssen; Stefan Endres; David Anz; Sebastian Kobold
Journal:  Oncoimmunology       Date:  2015-10-29       Impact factor: 8.110

View more
  19 in total

1.  γδ T Cell-Based Adoptive Cell Therapies Against Solid Epithelial Tumors.

Authors:  Xiomar Bustos; Sebastian Snedal; Leticia Tordesillas; Eleonora Pelle; Daniel Abate-Daga
Journal:  Cancer J       Date:  2022 Jul-Aug 01       Impact factor: 2.074

Review 2.  Targeting Cytokine Signals to Enhance γδT Cell-Based Cancer Immunotherapy.

Authors:  Yuan Song; Yonghao Liu; Huey Yee Teo; Haiyan Liu
Journal:  Front Immunol       Date:  2022-06-07       Impact factor: 8.786

Review 3.  Tumor-infiltrating lymphocytes in the immunotherapy era.

Authors:  Sterre T Paijens; Annegé Vledder; Marco de Bruyn; Hans W Nijman
Journal:  Cell Mol Immunol       Date:  2020-11-02       Impact factor: 11.530

4.  Aberrantly Expressed Embryonic Protein NODAL Alters Breast Cancer Cell Susceptibility to γδ T Cell Cytotoxicity.

Authors:  Gabrielle M Siegers; Indrani Dutta; Eun Young Kang; Jing Huang; Martin Köbel; Lynne-Marie Postovit
Journal:  Front Immunol       Date:  2020-06-19       Impact factor: 7.561

Review 5.  γδ T Cells: The Ideal Tool for Cancer Immunotherapy.

Authors:  Mahboubeh Yazdanifar; Giulia Barbarito; Alice Bertaina; Irma Airoldi
Journal:  Cells       Date:  2020-05-24       Impact factor: 6.600

6.  Vitamin C supports conversion of human γδ T cells into FOXP3-expressing regulatory cells by epigenetic regulation.

Authors:  Léonce Kouakanou; Christian Peters; Qiwei Sun; Stefan Floess; Jaydeep Bhat; Jochen Huehn; Dieter Kabelitz
Journal:  Sci Rep       Date:  2020-04-16       Impact factor: 4.379

7.  B7-H3 inhibits the IFN-γ-dependent cytotoxicity of Vγ9Vδ2 T cells against colon cancer cells.

Authors:  Huimin Lu; Tongguo Shi; Mingyuan Wang; Xiaomi Li; Yanzheng Gu; Xueguang Zhang; Guangbo Zhang; Weichang Chen
Journal:  Oncoimmunology       Date:  2020-04-14       Impact factor: 8.110

8.  Monocyte-dependent co-stimulation of cytokine induction in human γδ T cells by TLR8 RNA ligands.

Authors:  Ruben Serrano; Christoph Coch; Christian Peters; Gunther Hartmann; Daniela Wesch; Dieter Kabelitz
Journal:  Sci Rep       Date:  2021-07-27       Impact factor: 4.379

Review 9.  Vγ9Vδ2 T Cells: Can We Re-Purpose a Potent Anti-Infection Mechanism for Cancer Therapy?

Authors:  Klaus-Peter Künkele; Daniela Wesch; Hans-Heinrich Oberg; Martin Aichinger; Verena Supper; Christoph Baumann
Journal:  Cells       Date:  2020-03-30       Impact factor: 6.600

Review 10.  Functional Phenotypes of Human Vγ9Vδ2 T Cells in Lymphoid Stress Surveillance.

Authors:  Oliver Nussbaumer; Martin Thurnher
Journal:  Cells       Date:  2020-03-22       Impact factor: 6.600

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.